耐碳青霉烯类肠杆菌科细菌感染患者的临床结局、药物毒性及头孢他啶-阿维巴坦耐药性的出现
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
作者信息
Shields Ryan K, Potoski Brian A, Haidar Ghady, Hao Binghua, Doi Yohei, Chen Liang, Press Ellen G, Kreiswirth Barry N, Clancy Cornelius J, Nguyen M Hong
机构信息
Department of Medicine.
Antibiotic Management Program.
出版信息
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
Abstract
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.
摘要
37例碳青霉烯类耐药肠杆菌科细菌（CRE）感染患者接受了头孢他啶-阿维巴坦治疗。30天时的临床成功率和生存率分别为59%（22/37）和76%（28/37）。在23%（5/22）的临床成功病例中，CRE感染在90天内复发。微生物学失败率为27%（10/37）。在27%（3/10）的微生物学失败病例中检测到对头孢他啶-阿维巴坦耐药。
相似文献
1
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.耐碳青霉烯类肠杆菌科细菌感染患者的临床结局、药物毒性及头孢他啶-阿维巴坦耐药性的出现
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
2
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.多黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染。
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
3
Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.使用头孢他啶/阿维巴坦治疗复杂碳青霉烯类耐药肠杆菌科感染：一项结合分子菌株特征的回顾性研究。
Int J Antimicrob Agents. 2017 Jun;49(6):770-773. doi: 10.1016/j.ijantimicag.2017.01.018. Epub 2017 Apr 4.
4
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌感染患者结局的多中心研究
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00449-17. Print 2017 Jul.
5
Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.头孢他啶/阿维巴坦作为治疗产 OXA-48 碳青霉烯酶肠杆菌科感染的补救治疗的疗效。
J Antimicrob Chemother. 2018 Nov 1;73(11):3170-3175. doi: 10.1093/jac/dky295.
6
Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.治疗除肺炎克雷伯菌以外的耐药菌的头孢他啶/阿维巴坦的临床经验。
Int J Antimicrob Agents. 2018 Apr;51(4):629-635. doi: 10.1016/j.ijantimicag.2018.01.016. Epub 2018 Feb 2.
7
Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.产 OXA-48 碳青霉烯酶肠杆菌科细菌感染患者应用头孢他啶-阿维巴坦治疗的临床特征和预后
Int J Antimicrob Agents. 2019 Apr;53(4):520-524. doi: 10.1016/j.ijantimicag.2018.11.015. Epub 2018 Nov 22.
8
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.肺炎和肾脏替代治疗是耐碳青霉烯类肠杆菌科感染患者使用头孢他啶-阿维巴坦治疗失败和耐药的危险因素。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02497-17. Print 2018 May.
9
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Infections.美罗培南-维巴坦与头孢他啶-阿维巴坦治疗碳青霉烯类耐药感染。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02313-19.
10
The β-Lactams Strike Back: Ceftazidime-Avibactam.β-内酰胺类药物卷土重来：头孢他啶-阿维巴坦
Pharmacotherapy. 2015 Aug;35(8):755-70. doi: 10.1002/phar.1622.
引用本文的文献
1
Ceftazidime-Avibactam in Critically Ill Patients: A Multicenter Observational Study.头孢他啶-阿维巴坦用于重症患者：一项多中心观察性研究。
Antibiotics (Basel). 2025 Aug 5;14(8):797. doi: 10.3390/antibiotics14080797.
2
Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study.头孢他啶-阿维巴坦治疗耐碳青霉烯类微生物：一项前瞻性、观察性、单中心研究。
Antibiotics (Basel). 2025 Jul 31;14(8):773. doi: 10.3390/antibiotics14080773.
3
A network analysis of carbapenem-resistant Klebsiella pneumoniae among healthcare facilities.医疗机构中耐碳青霉烯类肺炎克雷伯菌的网络分析。
Sci Rep. 2025 Jul 29;15(1):27565. doi: 10.1038/s41598-025-04918-0.
4
A glycine at position 105 leads to clavulanic acid and avibactam resistance in class A β-lactamases.105位的甘氨酸会导致A类β-内酰胺酶对克拉维酸和阿维巴坦产生耐药性。
J Biol Chem. 2025 Jun 6;301(7):110347. doi: 10.1016/j.jbc.2025.110347.
5
Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy.在使用头孢他啶-阿维巴坦治疗期间获得革兰氏阴性菌的患者的临床特征
Infect Dis Ther. 2025 May;14(5):1027-1042. doi: 10.1007/s40121-025-01126-1. Epub 2025 Apr 2.
6
Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms.针对多重耐药和碳青霉烯耐药革兰氏阴性菌的新型抗生素：作用机制与耐药机制
Arch Microbiol. 2025 Apr 2;207(5):110. doi: 10.1007/s00203-025-04298-z.
7
New Kids on the Block: Estimating Use of Next-generation Gram-negative Antibiotics Across Greater Than 700 Hospitals in the United States.新兴力量：估算美国700多家医院中新一代革兰氏阴性菌抗生素的使用情况
Open Forum Infect Dis. 2025 Feb 12;12(2):ofaf079. doi: 10.1093/ofid/ofaf079. eCollection 2025 Feb.
8
Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis.联合治疗与单一疗法治疗耐碳青霉烯类革兰氏阴性菌感染的疗效：一项系统评价和荟萃分析。
Syst Rev. 2024 Dec 19;13(1):309. doi: 10.1186/s13643-024-02695-x.
9
A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.头孢他啶/阿维巴坦联合其他抗菌药物对耐碳青霉烯革兰氏阴性菌体外抗菌活性的系统评价及单菌属水平的Meta分析
J Antimicrob Chemother. 2025 Feb 3;80(2):334-346. doi: 10.1093/jac/dkae451.
10
A systematic review of efficacy and safety of newer drugs approved from 2016 to 2023 for the treatment of complicated urinary tract infections.2016 年至 2023 年批准用于治疗复杂性尿路感染的新药疗效和安全性的系统评价。
Ann Med. 2024 Dec;56(1):2403724. doi: 10.1080/07853890.2024.2403724. Epub 2024 Nov 12.
本文引用的文献
1
Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae.氨基糖苷类药物用于治疗耐碳青霉烯类肺炎克雷伯菌所致菌血症
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3187-92. doi: 10.1128/AAC.02638-15. Print 2016 May.
2
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.产KPC-3型肺炎克雷伯菌分离株中头孢他啶-阿维巴坦耐药性的首次报告
Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7. doi: 10.1128/AAC.01165-15. Epub 2015 Jul 20.
3
Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.肺炎克雷伯菌碳青霉烯酶亚型、超广谱β-内酰胺酶及孔蛋白突变对头孢他啶-阿维巴坦体外抗碳青霉烯类耐药肺炎克雷伯菌活性的影响
Antimicrob Agents Chemother. 2015 Sep;59(9):5793-7. doi: 10.1128/AAC.00548-15. Epub 2015 Jul 13.
4
In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.携带KPC-3碳青霉烯酶的肠杆菌科细菌对头孢他啶-阿维巴坦耐药性的体外筛选
Antimicrob Agents Chemother. 2015 Sep;59(9):5324-30. doi: 10.1128/AAC.00678-15. Epub 2015 Jun 22.
5
Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.序列类型为258、产KPC的肺炎克雷伯菌的多黏菌素MIC值和外膜孔蛋白OmpK36基因型可能预测菌血症患者对碳青霉烯类-黏菌素联合治疗的反应。
Antimicrob Agents Chemother. 2015 Mar;59(3):1797-801. doi: 10.1128/AAC.03894-14. Epub 2014 Dec 22.
6
Treating infections caused by carbapenemase-producing Enterobacteriaceae.治疗产碳青霉烯酶肠杆菌科细菌感染。
Clin Microbiol Infect. 2014 Sep;20(9):862-72. doi: 10.1111/1469-0691.12697. Epub 2014 Jul 12.
7
Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients.移植受者碳青霉烯类耐药肺炎克雷伯菌菌血症的流行病学和分子特征。
Am J Transplant. 2013 Oct;13(10):2619-33. doi: 10.1111/ajt.12424. Epub 2013 Sep 6.
8
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury.KDIGO 美国专家组关于 2012 年急性肾损伤临床实践指南的评论。
Am J Kidney Dis. 2013 May;61(5):649-72. doi: 10.1053/j.ajkd.2013.02.349. Epub 2013 Mar 15.
9
Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae.建立一套多重 PCR 检测方法，用于检测肠杆菌科中编码重要β-内酰胺酶的基因。
J Antimicrob Chemother. 2010 Mar;65(3):490-5. doi: 10.1093/jac/dkp498. Epub 2010 Jan 12.
Zotero 插件